Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial

Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10... BioDrugs (2017) 31:357–367 DOI 10.1007/s40259-017-0232-7 OR IGINAL RESEARCH ARTIC L E Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial 1 2 3 4 • • • • Dae Hyun Yoo Chang-Hee Suh Seung Cheol Shim Slawomir Jeka 5 6 7 • • • Francisco Fidencio Cons Molina Pawel Hrycaj Piotr Wiland 8 9 10 • • • Eun Young Lee Francisco G. Medina-Rodriguez Pavel Shesternya 11 12 13 • • • Sebastiao Radominski Marina Stanislav Volodymyr Kovalenko 14 15 16 17 • • • • Dong Hyuk Sheen Leysan Myasoutova Mie Jin Lim Jung-Yoon Choe 18 18 18 16 • • • Sang Joon Lee Sung Young Lee Sung Hwan Kim Won Park Published online: 13 June 2017 The Author(s) 2017. This article is an open access publication Abstract or RTX 1000 mg at weeks 0 and 2. Based on disease Background CT-P10 is a biosimilar of innovator ritux- activity, patients could receive a second course of treat- imab (RTX), a biological therapy used to treat patients ment between weeks 24 and 48. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png BioDrugs Springer Journals

Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial

Loading next page...
 
/lp/springer_journal/efficacy-safety-and-pharmacokinetics-of-up-to-two-courses-of-the-x3d1tDAEdi
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by The Author(s)
Subject
Biomedicine; Molecular Medicine; Antibodies; Cancer Research; Pharmacotherapy
ISSN
1173-8804
eISSN
1179-190X
D.O.I.
10.1007/s40259-017-0232-7
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial